Get solid data to base decisions on
Contract research services within diabetes
We have extensive experience of conducting preclinical diabetes studies in a variety of different rodent models of both type 1 and type 2 diabetes. We have a long track record of creating impact for our customers, when it comes to working with difficult models such as ZDF rats and db/db mice as well as quantitating beta-cell mass and other histological-pathological endpoints of diabetes.
Our scientific expertise within diabetes, combined with our effective CRO experience, provide solid data on which to base decisions. Furthermore, we have a high availability of animal enabling us to accelerate studies.
Our main offerings:
- Extensive experience with the majority of commercially available rodent models (C57BL/6, ob/ob, db/db mice as well as SPD and ZDF rats)
- Oral/intravenous/intraperitoneal glucose tolerance tests (OGTT, IVGTT, IPGTT) and insulin tolerance test (ITT)
- Continuous (24h) glucose monitoring in rats
- Insulin sensitivity testing (endogenous glucose production and tissue glucose uptake) using the hyperinsulinemic euglycemic clamp
- NOD mice and models of pancreatectomy
- RNA sequencing and bioinformatics
- Glucose infusion study
- Hyperinsulinemic-euglycemic clamp
Get in touch
Please get in touch if you are interested in discussing how to get started with your study.
Get in touch
Various type 2 diabetes rodent models
Type 1 diabetes model (Gubra PX rat)
The Gubra pancreatectomized (PX) rat is hyperglycemic from the time of PX and is ideal for anti-diabetic pharmacological testing and for modeling diabetic complications.
db/db mouse model
Our research has shown that the db/db mouse model is preferable for evaluating the potential proliferative effects of various interventions (pharmacological and non-pharmacological).
ZDF rat model
Thorough knowledge of the ZDF rat model is a must if you want to optimize your study design in accordance with drug type and mode of action. Take a look at our film on the subject to learn more about how this model can be used.
Dr. Michael Mark
Vice President | Boehringer Ingelheim